论文部分内容阅读
晚期胃癌预后差,化疗效果不佳。人类表皮生长因子受体2(HER2)从多个途径影响肿瘤细胞的生物活动,导致肿瘤的复发和转移。胃癌肠型比弥漫型HER2阳性表达率高,胃食管连接部HER2阳性表达率比胃部的高。Hercep Test评分标准可用于评估HER2表达水平。最近研究发现,部分胃癌患者存在HER2过表达是预后不良因素。曲妥珠单抗联合化疗有可能是未来治疗HER2过表达胃癌的标准方案。
Poor prognosis of advanced gastric cancer, poor chemotherapy. Human epidermal growth factor receptor 2 (HER2) affects the biological activity of tumor cells from multiple pathways, resulting in tumor recurrence and metastasis. The positive rate of HER2 expression in gastric cancer was higher than that in diffuse HER2, and the positive rate of HER2 expression in gastroesophageal junction was higher than that in stomach. Hercep Test score criteria can be used to assess HER2 expression levels. Recent studies have found that the presence of HER2 overexpression in some patients with gastric cancer is a poor prognostic factor. Trastuzumab combined with chemotherapy may be the future standard of treatment for HER2 overexpression of gastric cancer.